Joseph Leveque, M.D.

Joseph Leveque, M.D. is the Chief Medical Officer of Synthorx, a San Diego-based biotechnology company focused on therapeutic applications of synthetic biology in cancer and autoimmune disorders. Prior to joining Synthorx, Dr. Leveque was the Chief Medical Officer of ARMO BioSciences, a San Francisco Bay Area-based biotechnology company focused on the development of cytokines for the treatment of cancer.  Before joining ARMO, Dr. Leveque was the Chief Medical Officer of EMD Serono (EMDS), the US and Canadian subsidiary of Merck KGaA. At EMDS, Dr. Leveque focused on therapeutics for the treatment of cancer, neurodegenerative diseases, infertility, HIV-related complications and autoimmune disorders.  Prior to EMDS, Dr. Leveque was the Vice President and Head of U.S. Medical Oncology at Bristol-Myers Squibb, where he was involved in the development and commercialization of the first generation of IO therapeutics, ipilimumab and nivolumab. Before his role at Bristol-Myers Squibb, Dr. Leveque was the Vice President of Medical and Scientific Affairs at Onyx Pharmaceuticals, where he was involved in the development and commercialization of carfilzomib and sorafenib.  Before joining Onyx, Dr. Leveque was the Vice President of Oncology Medical and Scientific Affairs at Cephalon and a medical director at Amgen, where he worked on several therapeutic programs for solid tumor and hematological malignancies. Dr. Leveque obtained a Bachelor’s degree in Biology from Santa Clara University, an MBA from The Wharton School at the University of Pennsylvania and a M.D. from the University of Texas Medical School. He completed his internship and residency in internal medicine at the UCLA Cedars-Sinai Medical Center.